Cocaine Use Disorder Market Poised for Growth With Emerging Therapies

The market for cocaine use disorder (CUD) treatments is expected to see significant growth between 2026 and 2036. This expansion is anticipated due to the introduction of novel therapies, advancements in treatment options, improved healthcare access, and a rising prevalence of the condition. In 2025, the total CUD market across seven major regions—the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan—was valued at approximately USD 55 million, with substantial growth projected over the next decade.

The United States represented the largest market for CUD treatments in 2025. During the same year, an estimated 2.48 million cases of CUD were diagnosed, with numbers expected to increase significantly at a notable CAGR through 2036.

Key pharmaceutical companies, including STALICLA, Embera NeuroTherapeutics, and Omeros Corporation, are developing new CUD treatments aimed at reducing cravings and promoting abstinence. Promising drug candidates such as Mavoglurant and TMP-301 are currently in clinical trials and are anticipated to launch within the forecast period.

Currently, no pharmacological therapy has received U.S. Food and Drug Administration (FDA) approval specifically for cocaine use disorder. Existing treatments largely rely on off-label use of medications, including antidepressants and stimulants. However, the pipeline of emerging therapies offers potential for more effective treatment options in the future.